Related Experiment Video

Updated: May 18, 2026

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model
06:20

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Published on: September 1, 2023

ERP grants first action status to candidate tissue residue methods for high-priority animal drugs

Mark R Coleman1

  • 1Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA. coleman_mark_r@lilly.com

Journal of AOAC International
|September 14, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET17:13

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...